Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gross Profit (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Gross Profit for 7 consecutive years, with $126.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 5.29% year-over-year to $126.5 million, compared with a TTM value of $501.7 million through Dec 2025, up 18.64%, and an annual FY2025 reading of $501.7 million, up 18.64% over the prior year.
  • Gross Profit was $126.5 million for Q4 2025 at Catalyst Pharmaceuticals, up from $125.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $126.5 million in Q4 2025 and bottomed at $25.5 million in Q1 2021.
  • Average Gross Profit over 5 years is $78.5 million, with a median of $86.8 million recorded in 2023.
  • The sharpest move saw Gross Profit plummeted 72.85% in 2021, then soared 102.75% in 2023.
  • Year by year, Gross Profit stood at $31.0 million in 2021, then skyrocketed by 60.08% to $49.6 million in 2022, then soared by 91.19% to $94.8 million in 2023, then rose by 26.82% to $120.2 million in 2024, then rose by 5.29% to $126.5 million in 2025.
  • Business Quant data shows Gross Profit for CPRX at $126.5 million in Q4 2025, $125.7 million in Q3 2025, and $125.9 million in Q2 2025.